List of Figures
Figure 1: Global Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 2: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 3: Global Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 4: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 5: Global Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 6: Global Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 7: Global Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 8: Global Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 9: Global Gene Therapy Market, By Vector Type, 2019, 2025
Figure 10: Global Gene Therapy Market - By Lentivirus, By Value (USD Million), 2015-2025
Figure 11: Global Gene Therapy Market - By AAV, By Value (USD Million), 2015-2025
Figure 12: Global Gene Therapy Market - By Retrovirus and Gammaretrovirus, By Value (USD Million), 2015-2025
Figure 13: Global Gene Therapy Market – By Others, By Value (USD Million), 2015-2025
Figure 14: Global Gene Therapy Market, By Application, 2019, 2025
Figure 15: Global Gene Therapy Market - By Neurological Disorders, By Value (USD Million), 2015-2025
Figure 16: Global Gene Therapy Market - By Cancer, By Value (USD Million), 2015-2025
Figure 17: Global Gene Therapy Market - By Cardiovascular Disorders, By Value (USD Million), 2015-2025
Figure 18: Global Gene Therapy Market - By Others, By Value (USD Million), 2015-2025
Figure 19: Global Gene Therapy Market, By Region, 2019, 2025
Figure 20: North America Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 21: North America Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 22: North America Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 23: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 24: North America Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 25: North America Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 26: North America Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 27: North America Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 28: North America Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 29: North America Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 30: Market Opportunity Chart of North America Gene Therapy Market - By Country, By Value, 2025
Figure 31: North America Gene Therapy Market, By Country, 2019, 2025
Figure 32: United States Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 33: United States Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 34: United States Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 35: United States Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 36: United States Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 37: United States Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 38: United States Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 39: United States Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 40: United States Average Income and Expenditures of All Consumer Units, 2017, 2018 (In %)
Figure 41: United States Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 42: United States Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 43: Canada Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 44: Canada Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 45: Canada Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 46: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 47: Canada Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 48: Canada Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 49: Canada Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 50: Canada Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 51: Canada Average Income and Expenditures of All Consumer Units, 2017, 2018 (In %)
Figure 52: Canada Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 53: Canada Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 54: Europe Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 55: Europe Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 56: Europe Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 57: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 58: Europe Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 59: Europe Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 60: Europe Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 61: Europe Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 62: European Union Household Expenditure, By Consumption Purpose, 2018 (In %)
Figure 63: Europe Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 64: Europe Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 65: Market Opportunity Chart of Europe Gene Therapy Market - By Country, By Value, 2025
Figure 66: Europe Gene Therapy Market, By Country, 2019, 2025
Figure 67: Germany Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 68: Germany Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 69: Germany Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 70: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 71: Germany Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 72: Germany Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 73: Germany Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 74: Germany Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 75: Germany Household Expenditure, By Consumption Purpose, 2018 (In %)
Figure 76: Germany Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 77: Germany Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 78: France Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 79: France Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 80: France Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 81: France Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 82: France Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 83: France Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 84: France Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 85: France Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 86: France Household Expenditure, By Consumption Purpose, 2018 (In %)
Figure 87: France Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 88: France Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 89: United Kingdom Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 90: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 91: United Kingdom Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 92: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 93: United Kingdom Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 94: United Kingdom Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 95: United Kingdom Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 96: United Kingdom Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 97: United Kingdom Household Expenditure, By Consumption Purpose, 2018 (In %)
Figure 98: United Kingdom Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 99: United Kingdom Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 100: Italy Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 101: Italy Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 102: Italy Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 103: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 104: Italy Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 105: Italy Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 106: Italy Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 107: Italy Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 108: Italy Household Expenditure, By Consumption Purpose, 2018 (In %)
Figure 109: Italy Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 110: Italy Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 111: Asia Pacific Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 112: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 113: Asia Pacific Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 114: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 115: Asia Pacific Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 116: Asia Pacific Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 117: Asia Pacific Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 118: Asia Pacific Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 119: Asia Pacific Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 120: Asia Pacific Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 121: Market Opportunity Chart of Asia Pacific Gene Therapy Market - By Country, By Value, 2025
Figure 122: Asia Pacific Gene Therapy Market, By Country, 2019, 2025
Figure 123: China Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 124: China Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 125: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 126: China Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 127: China Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 128: China Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 129: China Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 130: China Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 131: China Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 132: China Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 133: Japan Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 134: Japan Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 135: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 136: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 137: Japan Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 138: Japan Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 139: Japan Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 140: Japan Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 141: Japan Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 142: Japan Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 143: India Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 144: India Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 145: India Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 146: India Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 147: India Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 148: India Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 149: India Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 150: India Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 151: India Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 152: India Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 153: South Korea Gene Therapy Market Size, By Value, 2015-2025 (USD Million)
Figure 154: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 155: South Korea Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 156: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 157: South Korea Prevalence of Schizophrenia, 2015-2019 (In Millions)
Figure 158: South Korea Prevalence of Alzheimer's Disease and Other Dementias, 2015-2019 (In Millions)
Figure 159: South Korea Prevalence of Sickle Cell Disorders, 2015-2019 (In Millions)
Figure 160: South Korea Prevalence of Mesothelioma, 2015-2019 (In Thousands)
Figure 161: South Korea Gene Therapy Market - By Vector Type, By Value, 2015-2025 (USD Million)
Figure 162: South Korea Gene Therapy Market - By Application, By Value, 2015-2025 (USD Million)
Figure 163: Market Attractiveness of Global Gene Therapy Market - By Vector Type, 2025
Figure 164: Market Attractiveness of Global Gene Therapy Market - By Application, 2025
Figure 165: Market Attractiveness of Global Gene Therapy Market - By Region, 2025
Figure 166: Market Share of Leading Global Gene Therapy Companies, 2019 (In %)
Figure 167: Voyager Therapeutics Revenue, 2015-2019 (In USD Million)
Figure 168: Novartis AG Revenue, 2015-2019 (In USD Billion)
Figure 169: Novartis AG Net Revenue, By Business Segment, 2018 (In %)
Figure 170: Novartis AG Net Revenue, By Business Segment, 2019 (In %)
Figure 171: Novartis AG Net Revenue, By Geographic Segment, 2018 (In %)
Figure 172: Novartis AG Net Revenue, By Geographic Segment, 2019 (In %)
Figure 173: Roche Group Revenue, 2016-2019 (In USD Billion)
Figure 174: Roche Group Net Revenue, By Business Segment, 2018 (In %)
Figure 175: Roche Group Net Revenue, By Business Segment, 2019 (In %)
Figure 176: Roche Group Net Revenue, By Geographic Segment, 2018 (In %)
Figure 177: Roche Group Net Revenue, By Geographic Segment, 2019 (In %)
Figure 178: Orchard Therapeutics PLC Revenue, 2018-2019 (In USD Million)
Figure 179: Alnylam Pharmaceuticals Inc. Revenue, 2015-2019 (In USD Million)
Figure 180: Alnylam Pharmaceuticals Inc. Net Revenue, By Geographic Region, 2018 (In %)
Figure 181: Alnylam Pharmaceuticals Inc. Net Revenue, By Geographic Region, 2019 (In %)
Figure 182: AnGes Inc. Revenue, 2015-2019 (In USD Million)
Figure 183: Akcea Therapeutics Revenue, 2015-2019 (In USD Million)
Figure 184: BlueBird Bio Inc. Revenue, 2015-2019 (In USD Million)
Figure 185: Sarepta Therapeutics Revenue, 2015-2019 (In USD Million)
